Mytos is developing a fully automated platform for the manufacture of any human cell type, utilizing advanced robotics and software to streamline cell culture processes. This technology addresses the challenges of contamination and human error in cell production, enabling consistent, high-quality output at a scale that allows one technician to achieve the productivity of ten scientists working manually.
Funding
$64M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AC+1Founders
Product
Problem
Manufacturing human cells for drug discovery and cell therapies is a complex process that is prone to contamination and human error. Traditional cell culture methods require highly skilled scientists and are difficult to scale, resulting in inconsistent cell quality and limiting production volume.
Solution
Mytos offers the iDEM™ platform, an automated cell manufacturing solution designed to produce consistent, high-quality human cells at scale. The platform integrates advanced robotics, software, and purpose-built bioreactors to automate cell culture workflows, reducing the need for manual intervention. By automating cell production, Mytos enables a single technician to achieve the output of ten scientists working manually, while also minimizing the risk of contamination and batch failures. The iDEM™ platform supports a variety of human cell types, including primary suspension cells and induced pluripotent stem cells (iPSCs).
Target Audience
Mytos serves pharmaceutical companies and cell therapy developers seeking to streamline cell manufacturing, improve cell quality, and increase production throughput.
Features
- Fully automated cell culture processes from cell expansion to harvest
- Integrated robotics system for precise liquid handling and cell manipulation
- Real-time monitoring and control of critical process parameters (e.g., temperature, pH, dissolved oxygen)
- Closed system design to minimize contamination risk
- Software-driven workflow management and data tracking
- Compatibility with a range of human cell types, including iPSCs
- Scalable architecture to support increasing cell production demands